Karyopharm Files 8-K Furnishing Press Release (Exhibit 99.1) on Q2 Results

Rhea-AI Filing Summary

Karyopharm Therapeutics reported that it has announced its financial results for the quarter ended June 30, 2025 and will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The Form 8-K states the full press release with details is furnished as Exhibit 99.1 and is incorporated by reference into the report.

The filing clarifies that the information in this report and Exhibit 99.1 is furnished, not filed, and therefore is not subject to Section 18 liability or automatic incorporation by reference in other Securities Act or Exchange Act filings. The Form 8-K itself does not include the financial figures in-line; investors must review Exhibit 99.1 for the substantive results.

Positive

• Press release furnished as Exhibit 99.1, enabling investors to access the company's announced results and updates.
• Previously announced, publicly available conference call will allow investors and analysts to hear management commentary and Q&A.

Negative

• No financial figures or tables are included within the text of this Form 8-K, preventing assessment of performance from this filing alone.
• Exhibit is furnished, not filed, which limits Section 18 liability and may affect how the disclosure is treated in subsequent filings.

Insights

Financial Analyst

TL;DR: Routine earnings disclosure lacking in-line metrics; investors need Exhibit 99.1 to evaluate performance.

The 8-K confirms that Karyopharm announced results for the quarter ended June 30, 2025 and will host a previously announced public conference call. However, the filing does not present the underlying financial figures or metrics directly; instead it furnishes a press release as Exhibit 99.1. Because the substantive data are not included in this filing, the 8-K alone provides limited basis for financial analysis. Analysts should obtain and review Exhibit 99.1 and any conference call materials for revenue, earnings, cash flow, guidance, or other performance indicators.

Corporate Governance Expert

TL;DR: Standard Form 8-K disclosure process used; no governance changes or material qualifiers disclosed here.

The report follows standard disclosure practice by furnishing a press release and noting a public call. The filing explicitly states Exhibit 99.1 is furnished, not filed, which limits Section 18 liability and signals a routine information release rather than an amendment to previously filed SEC statements. There is no indication in this 8-K of executive changes, material contracts, related-party transactions, or corrective disclosures. Governance implications are minimal based solely on the content provided.

false000150380200015038022025-08-112025-08-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 11, 2025

Karyopharm Therapeutics Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware		001-36167				26-3931704
(State or Other Jurisdiction of Incorporation)		(Commission File Number)				(IRS Employer Identification No.)
85 Wells Avenue, 2nd Floor Newton, Massachusetts				02459
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s telephone number, including area code: (617) 658-0600

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		KPTI		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2025, Karyopharm Therapeutics Inc. announced its financial results for the quarter ended June 30, 2025 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit 99.1 relating to Item 2.02 shall be deemed to be furnished, and not filed:

Exhibit No.		Description
99.1		Press Release issued by Karyopharm Therapeutics Inc. on August 11, 2025
104		Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				KARYOPHARM THERAPEUTICS INC.
Date: August 11, 2025				By:		/s/ Michael Mano
						Michael Mano
						Senior Vice President, General Counsel and Secretary

FAQ

What did Karyopharm (KPTI) announce in this Form 8-K?

The company announced its financial results for the quarter ended June 30, 2025 and that it will conduct a previously announced, publicly available conference call to discuss those results and other updates.

Where can I find the detailed financial results for KPTI?

The detailed results are contained in the press release furnished as Exhibit 99.1 to this Form 8-K; the 8-K text does not include the financial figures in-line.

Is the press release in Exhibit 99.1 filed with the SEC?

No. The Form 8-K states the press release is furnished, not filed, and therefore not subject to Section 18 liability or automatically incorporated by reference in other filings.

Does this filing include the conference call date and time?

The 8-K notes a previously announced, publicly available conference call will be conducted, but this filing does not provide a specific date or time for the call.

Does the 8-K report any material transactions or executive changes?

No. This Form 8-K is limited to results of operations and the accompanying press release; it does not disclose any material transactions or leadership changes.